We’re proud our parnter @ZEROCancer is raising national awareness around prostate cancer screening during the #SuperBowl.
Early detection starts with a simple PSA test, and changing the conversation can change outcomes.
https://t.co/RIS451kq40
#MensHealth#RelaxItsABloodTest
Snowstorms in Vail. Sunshine in Florida.
Grateful for quality time with the community at both #IPCU2026 and #ACRO2026 last week.
Thanks to everyone who joined us, always inspired by the conversations driving cancer care forward.
#ArteraAI#Oncology
Catch the Artera team at both the @MayoClinic Urology Review in Kamuela, HI and the Aspen Urological Conference in Aspen, CO.
Let’s talk AI, innovation & prostate cancer care. See you there!
#Urology#ProstateCancer#ArteraAI
Attending #ACRO2026? Don’t miss Dr. Douglas Rivera and Dr. Ben Fischer-Valuck in a case-based session on using the ArteraAI Prostate Test in localized prostate cancer care.
Register: https://t.co/qEF6upquuZ
#ArteraAI
Grateful to @UroToday, Dr. Paul Nguyen, and Dr. Zach Klaassen for highlighting our AI-powered prognostic test in the salvage radiation therapy setting.
Watch the full interview: https://t.co/8LFS7mc7ju
#ProstateCancer#ArteraAI
Excited to join the 2026 @IowaUrology Annual Conference in Galena, IL! Looking forward to connecting with the UCI team to talk AI + precision care in urology.
#Urology#ArteraAI#ProstateCancer
Dr. Daniel Spratt on Artera’s Post‑RP test:
“[It] uses clinical and pathologic features + digital pathology, running AI to help ID patients at low vs high risk of recurrence and metastasis.”
Thanks @UroTimes + Hannah Clarke for the feature.
https://t.co/81ShDfFaKT
#ArteraAI
Recently published in @EUplatinum!
Study led by Dr. Todd Morgan supports the utility of the ArteraAI Prostate Test (Post-RP) in guiding care for patients with biochemical recurrence.
https://t.co/C5QzUEnb7P
#ProstateCancer#ArteraAI#DigitalPathology#Urology
See you in Utah! The Artera team is excited to attend the @UrologyUS Global Prostate Cancer Congress and share how AI is helping improve care across the prostate cancer journey. #GPCCongress#ProstateCancer#ArteraAI
Excited to join the Mayo Clinic Radiation Oncology Course in Kauai January 5-9, 2026! Looking forward to great discussions on the future of prostate cancer care. #RadiationOncology#ArteraAI
2025 was a milestone year for Artera: innovation, clinical impact, and recognition for AI-driven oncology. From FDA authorizations and major trials to CEO Andre Esteva in TIME 100, we’re proud of the progress, and excited to expand into breast cancer in 2026.
We’re proud to see @UroToday highlight the commercial launch of the ArteraAI Prostate Test (Post-RP), expanding our oncology portfolio to support patients experiencing biochemical recurrence after radical prostatectomy: https://t.co/H5xQ8pNKt8
This Thanksgiving, we’re thankful for:
🧠 Research collaborators
🩺 Clinicians using our tools
💙 The patients we serve
🤝 Partners like CorePlus & @PathNetLab
Grateful to work alongside you in advancing personalized prostate cancer care.
#ArteraAI#AIinHealthcare
We are excited to share 3 key data presentations at @SABCS, showcasing the validation of our #MMAI model in early-stage #breastcancer across multiple Phase III trials in over 12,000 patients from across the world.
Read more here:
https://t.co/7lDurtCHdq
Prostate cancer affects everyone differently. AI can help doctors spot patterns in biopsy images to guide decisions, like whether short-term ADT with radiation may help. Because cancer is personal, therapy should be too.
Learn more in this summary of our predictive validation: